Posted by Michael Wonder on 17 Jun 2020
Ipsen receives FDA fast track designation for liposomal irinotecan (Onivyde) as a first-line combination treatment for metastatic pancreatic cancer
17 June 2020 - Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO World Congress on Gastrointestinal Cancer on 1July 2020.
Ipsen today announced the United States FDA has granted the company fast track designation for the investigational use of liposomal irinotecan (Onivyde) in combination with 5- fluorouracil/leucovorin and oxaliplatin together, known as NALIRIFOX for patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.
